Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

A MOTHER has revealed that she lost over seven stone in just seven months after taking weight loss drug Mounjaro. Layla Angus ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Discover the truth behind Nerve Fresh reviews with our detailed article – does this nerve pain supplement really work or is ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Telehealth company Hims & Hers (HIMS) saw a major boost in app downloads during February. According to a Top-rated analyst, Craig ...

Hims & Hers Health, Inc. (NYSE:HIMS) recently launched a weight-loss portfolio, which was met with huge success. The offerings, which include oral weight loss and compounded GLP-1 injections, not only ...